EOR #4 pharm part 2 Flashcards
Dosage forms of Advair Diskus
100/50, 250/50, 500/50
Average daily doses of Advair Diskus
One Diskus inhalation twice daily, approximately 12 hrs apart.
For ages 4 yrs and older
Common indications for Advair Diskus
Long-term maintenance treatment of asthma, COPD
MOA of Advair Diskus
Fluticasone is a corticosteroid that has extremely potent vasoconstrictive and anti-inflammatory activity
Salmeterol relaxes bronchial smooth muscle by selective action on beta2-receptors with little effect on heart rate
Common AEs of Advair Diskus
Upper respiratory tract infection Pharyngitis HA Sinusitis Bronchitis Rash
BBW for Advair Diskus
LABAs such as salmeterol may increase the risk of asthma-related death
Clinically sig drug interactions with Advair Diskus
Corticosteroids, sympathomimetics, TCAs, and MAOIs may increase toxicity
BBs may decrease the effectiveness of salmeterol
Major counseling points of Advair Diskus
Avoid contact with eyes
Rinse mouth after use
Not intended for immediate relief of sx
Use on a regular basis for full effect
Monitoring parameters of Advair Diskus
PFTs
Proper technique
S/sx of asthma/COPD
Dosage forms of methylprednisolone
2 mg, 4 mg, 8 mg, 16 mg, 32 mg,
Dosepak: 4 mg
Average daily doses of methylprednisolone`
4-48 mg/day
Common indications for methylprednisolone
Allergic or inflammatory dz
MS
MOA of methylprednisolone
Regulate gene expression subsequent to binding specific intracellular receptors and translocation into the nucleus
Modulate carbs, protein, and lipid metabolism and maintenance of fluid and electrolyte homeostasis
CV, immunologic, musculoskeletal, endocrine, and neurologic physiology are influenced
Decreases inflammation by suppression of PMN leukocytes and reversal of increased capillary permeability
Common AEs of methylprednisolone
Blurred vision Upset stomach Nausea Vomiting Fluid and electrolyte disturbances Agitation Insomnia Long-term Cushings Osteoporosis
BBWs for methylprednisolone
Epidural corticosteroid injection may cause neurologic complications
Clinically significant drug interactions with methylprednisolone
Anticholinesterase
Barbiturates
Estrogens
Ketoconazole
Major counseling points of methylprednisolone
Take with or without food
Do not d/c on your own
DM pts could see an increase in BG readings
Monitoring parameters of methylprednisolone
S/sx of inflammation
BG
Dosage forms of paroxetine
Tabs: 10 mg, 20 mg, 30 mg, 40 mg
Controlled-release tabs: 12.5 mg, 25 mg, 37.5 mg
Oral suspension: 10 mg/5 mL
Average daily dosages of paroxetine
25 mg to 62.5 mg daily
Common indications for paroxetine
Depression
Panic d/o
OCD
GAD
MOA of paroxetine
SSRI, clinically unrelated to tricyclic, tetracyclic, or other antidepressants
Presumably, the inhibition of serotonin reuptake from brain synapse stimulated serotonin activity in the brain
Common AEs of paroxetine
Nausea Somnolence HA Sexual dysfunction Dizziness Asthenia Wt gain
Renal or hepatic dose adjustments for paroxetine
CrCl <30 mL/min: adjustment needed
Severe hepatic impairment: adjustment needed
BBW for paroxetine
Increased suicidal thinking and behavior
Clinically sig drug interactions for paroxetine
MAOIs
Chronic use with NSAIDs increases risk of GI bleed
Major counseling points for paroxetine
May cause drowsiness.
Avoid EtOH while taking this med
Therapy may take up to 2 wks to see improvement
Do not abruptly d/c
Pay close attention to any changes in mood, thought, or feelings such as suicidality
Monitoring parameters of paroxetine
Improvement of S/sx of depression/panic/GAD/OCD
Unusual changes in mood
Suicidality
Dosage forms of clonidine
Tabs: 0.1, 0.2, 0.3 mg
ER tabs: 0.17 mg
Transdermal XR patch: 0.1 mg/hr, 0.2 mg/hr, 0.3 mg/hr
Average daily dosages of clonidine
0.1-0.3 mg/day
Common indications of clonidine
HTN
Opioid detox
Impulse control/ADHD
MOA of clonidine
Central pre-synaptic alpha 2 receptor antagonist
Reduces the brain’s adrenergic outflow to decrease BP
Common AEs of clonidine
Drowsiness Xerostomia HA Bradycardia Rash (transdermal patch) Dizziness Somnolence
Clinically sig drug interactions of clonidine
TCAs may cause severe hypotension
Avoid CNS depressants
Major counseling points of clonidine
Do not d/c abruptly d/t rebound HTN
Patches are applied on a weekly basis
Patch site must be rotated on a weekly basis
Monitoring parameters of clonidine
Decrease in BP
Improvement of S/sx of ADHD/impulse control